DE60335404D1 - Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges - Google Patents

Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges

Info

Publication number
DE60335404D1
DE60335404D1 DE60335404T DE60335404T DE60335404D1 DE 60335404 D1 DE60335404 D1 DE 60335404D1 DE 60335404 T DE60335404 T DE 60335404T DE 60335404 T DE60335404 T DE 60335404T DE 60335404 D1 DE60335404 D1 DE 60335404D1
Authority
DE
Germany
Prior art keywords
eye
treatment
aminochinolin
compounds
inflammatory illnesses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335404T
Other languages
English (en)
Inventor
Rajeev Raut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60335404D1 publication Critical patent/DE60335404D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60335404T 2002-05-17 2003-05-14 Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges Expired - Lifetime DE60335404D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38092602P 2002-05-17 2002-05-17
PCT/IN2003/000189 WO2003097025A2 (en) 2002-05-17 2003-05-14 A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom

Publications (1)

Publication Number Publication Date
DE60335404D1 true DE60335404D1 (de) 2011-01-27

Family

ID=29550039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335404T Expired - Lifetime DE60335404D1 (de) 2002-05-17 2003-05-14 Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges

Country Status (7)

Country Link
US (1) US7084157B2 (de)
EP (1) EP1558254B1 (de)
AT (1) ATE491453T1 (de)
AU (1) AU2003249575A1 (de)
DE (1) DE60335404D1 (de)
PT (1) PT1558254E (de)
WO (1) WO2003097025A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273366B2 (en) * 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
US20120058993A1 (en) * 2003-07-23 2012-03-08 Douglas Pharmaceuticals Ltd. Stable Suspension Formulation
GB0406014D0 (en) * 2004-03-17 2004-04-21 Arakis Ltd Pharmaceutical composition and use
US8895521B2 (en) * 2004-05-06 2014-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
WO2006120696A2 (en) * 2005-02-21 2006-11-16 Rajeev Raut An improved pharmaceutical composition
WO2006108666A1 (en) * 2005-04-13 2006-10-19 Proteosys Ag Mefloquine, nelfinavir and saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
CN101355876B (zh) * 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
US8114892B2 (en) * 2006-02-16 2012-02-14 The Mclean Hospital Corporation Methods and compositions for the treatment of Parkinson's Disease
WO2008043075A2 (en) * 2006-10-05 2008-04-10 Wyeth Compositions for the treatment of scleritis
WO2009089401A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using same
WO2009089399A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
TWI772270B (zh) 2015-08-18 2022-08-01 美商安斯泰來再生醫藥協會 臨床調配物
RU2019121873A (ru) 2016-12-13 2021-01-15 БЕТА ТЕРАПЬЮТИКС ПиТиУай ЛТД Ингибиторы гепараназы и их применение
WO2018107226A1 (en) * 2016-12-13 2018-06-21 Beta Therapeutics Pty. Ltd. Methods of treating ocular disorders
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN113318231A (zh) * 2020-02-28 2021-08-31 上海医药集团股份有限公司 一种4-氨基喹啉类化合物的应用
CN114796216A (zh) * 2022-01-04 2022-07-29 南京医科大学 甲氟喹在防治全身代谢性炎症疾病中的应用
CN114920694B (zh) * 2022-07-18 2022-11-08 康瑞鑫(天津)药物研究院有限公司 羟氯喹粗品的精制方法及制备的羟氯喹产品

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498187A1 (fr) * 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
RO92640A2 (ro) * 1985-05-13 1987-09-30 Institutul De Medicina Si Farmacie,Ro Metoda pentru tratamentul keratitelor virotice
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
CA2133620A1 (en) * 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
KR100263802B1 (ko) * 1995-11-16 2001-01-15 프리돌린 클라우스너, 롤란드 비. 보레르 항말라리아성 퀴놀린 유도체
US20020091139A1 (en) * 1997-10-17 2002-07-11 Damon Todd Holdings, L.L.C. Treatment and delivery of hydroxychloroquine
US6384081B2 (en) * 1998-10-09 2002-05-07 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
JP2005512998A (ja) * 2001-11-09 2005-05-12 ローレン チャロウス、 抗マラリア治療剤に対する新規の使用

Also Published As

Publication number Publication date
EP1558254B1 (de) 2010-12-15
WO2003097025B1 (en) 2004-03-18
US7084157B2 (en) 2006-08-01
AU2003249575A1 (en) 2003-12-02
WO2003097025A2 (en) 2003-11-27
PT1558254E (pt) 2011-02-15
US20030216431A1 (en) 2003-11-20
WO2003097025A3 (en) 2004-02-12
EP1558254A2 (de) 2005-08-03
AU2003249575A8 (en) 2003-12-02
ATE491453T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
DE60335404D1 (de) Verwendung von 4-aminochinolin-verbindungen zur behandlung entzündlicher erkrankungen des auges
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
EA200601239A1 (ru) Замещённые хинолиновые соединения
ATE202346T1 (de) Benzofuran derivate und ihre verwendung als inhibitoren der knochenresorption
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
EA200970637A1 (ru) 2-замещенные-6-гетероциклилпроизводные пиримидона в качестве ингибиторов тау-протеинкиназы
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
NO20060718L (no) Substituerte tiofoner og deres anvendelse
DK1745010T3 (da) Substituerede cyklohexyl-1,4-diaminderivater
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
NO20054418L (no) Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
EA200401432A1 (ru) Сложноэфирные производные декагидроизохинолин-3-карбоновой кислоты в качестве анальгетиков
DE50312458D1 (de) Iminosäurederivate als inhibitoren von matrix-metalloproteinasen
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors